Skip to main content

Table 1 Patient and tumor characteristics

From: CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

Characteristic

Number of patients (percentage)

Age

 

   <50 years

19 (42)

   ≥50 years

26 (58)

HER-2 a

 

   IHC (score 3+)

26 (58)

   FISH-positive

42 (95)

Estrogen receptor-positive

 

   Yes

17 (38)

   No

28 (62)

Progesterone receptor-positive

 

   Yes

10 (22)

   No

35 (78)

Nuclear grade

 

   Intermediate

14 (31)

   High

31 (69)

Tumor size (baseline)

 

   T1

5 (11)

   T2

24 (53)

   T3

8 (18)

   T4

8 (18)

Nodal status (baseline)

 

   N0

19 (42)

   N1-N3

26 (58)

  1. aAll tumors were HER-2-positive by either IHC (score, 3+) and/or FISH. Not every patient had both tests. Two tumors were 2+ by IHC and positive by FISH, and one tumor was 3+ by IHC and negative by FISH. FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.